Actively Recruiting
Phase 1 Trial of APX-343A Alone or with Pembrolizumab to Evaluate Safety and Preliminary Effects in Advanced Solid Tumors
Led by Aptabio Therapeutics, Inc. · Updated on 2026-10-09
110
Participants Needed
3
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics, and initial effectiveness of APX-343A alone and in combination with pembrolizumab in adults with advanced solid tumors. This study aims to better understand how these treatments behave in the body and their potential effects in this patient group. The study has two parts Part A tests increasing doses of APX-343A by itself, while Part B tests increasing doses of APX-343A together with pembrolizumab. APX-343A is given orally twice daily, and pembrolizumab is administered intravenously. Participants receive the assigned treatment to assess safety and determine appropriate doses. Participants will be monitored from enrollment through 90 days after treatment ends to evaluate safety and tolerability. Researchers will also measure drug levels in the body during the first three weeks and assess tumor response over about one year. The study involves regular assessments including tumor biopsies, imaging, and health status evaluations to track outcomes and effects.
CONDITIONS
Brief Title
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Research Team
C
Clinical Center, Clinical Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here